Date: 2012-03-16
Type of information: Nomination
Compound:
Company: AM-Pharma (The Netherlands)
Therapeutic area: Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 16, 2012. AM?Pharma announced that the company has appointed Dr Guido Magni as a member of
its Supervisory Board. Dr Magni MD PhD was trained as an MD with a specialization in neuropharmacology. He was previously the global head of the medical science department of Roche Pharmaceuticals, Basel, Switzerland, a post
he held for 12 years. During this time he was responsible for the development and the approval of a large number of New Molecular/Biological Entities including Cellcept®, Pegasys®, Xeloda®, Herceptin®,Tamiflu®, Tarceva® and Mabthera®. In his position as global head he defined and ensured the implementation of the overall strategies, goals and objectives of the department, with responsibility for drug development from first in human trials right through to registration and post?marketing approval. Dr Magni also is venture partner of Versant, with oversight of Versant’s European activities. Furthermore, Dr Magni serves as a board member of Biotie and was a board member of Adolor
Corporation, recently sold to Cubist, and Anabasis, recently sold to Dompe. Dr Magni is the author of more than 100 papers published in internationally peer reviewed journals.
David Brister, who has been a supervisory board member of AM?Pharma for 3 years, will step down from the board.
Financial terms:
Latest news:
